GISE 2017 – MILANO 10-13 OTTOBRE

ENDOTECH SARA’ PRESENTE AL GISE 2017 – VISITA IL NS. STAND # 48

MILANO – MICO CONGRESS CENTRE

10 – 13 OTTOBRE 2017

INSIEME AI NOSTRI PARTNERS PRESENTEREMO:

Neovasc Provides Tiara™ Clinical Update

Neovasc Provides Tiara™ Clinical Update.

Sep 12, 2017

NASDAQ, TSX: NVCN

VANCOUVER, Sept. 12, 2017 /CNW/ – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) today provided an update on the study progress and clinical performance of the TiaraTM valve, a self-expanding mitral bioprosthesis for transcatheter implantation in patients with Mitral Regurgitation (“MR”), one of the most prevalent valvular heart diseases in western countries. MR is often severe and can lead to heart failure and death.

Read more

PISA CULT 2017

Endotech sarà presente al Pisa CULT 2017

il 13/09/2017

Nella sezione “Mitral Valve Replacement”

Presentazione @TIARA NEOVASC

Prof. S.Banai

REDUCER SYSTEM

The coronary sinus reducer: clinical evidence and technical aspects

Francesco GianniniAndrea AurelioRichard J. JabbourLuca FerriAntonio Colombo & Azeem Latib

Pages 47-58 | Received 26 Sep 2016, Accepted 07 Dec 2016, Accepted author version posted online: 09 Dec 2016, Published online: 15 Dec 2016

ABSTRACT

Introduction: Chronic refractory angina is often a disabling condition, predominantly due to severe obstructive coronary artery disease, that is inadequately controlled by optimal medical therapy and not amenable to further percutaneous or surgical revascularization. mortality rates associated with this condition are relatively low in clinically stable patients. however, it is associated with a high hospitalization rate and a reduction in both exercise capacity and quality of life. due to the paucity of available treatment options, there is an unmet need for new therapies for these patients and for a reduction in the associated economic healthcare burden.

Areas covered: This review is focusing on the clinical evidence and technical aspects of this new therapeutic modality in refractory angina patients unsuitable for revascularization.

Expert commentary: The Coronary Sinus Reducer (Neovasc Inc. Richmond B.C., Canada) is a new percutaneous device designed to achieve a controlled narrowing of the coronary sinus that may alleviate myocardial ischemia, possibly by redistributing blood from the less ischemic sub-epicardium to the more ischemic sub-endocardium, or by neoangiogenesis. Recently, a randomized, double-blind, multi-center clinical trial demonstrated a benefit in improving symptoms in 104 refractory angina patients, when compared to placebo.

KEYWORDS: Coronary sinus reducer implantationrefractory anginacoronary artery diseaseangina pectorismyocardial ischemia

1 2